The world's first malaria vaccine – promising clinical results
Work on the malaria vaccine has been going on since the early 20st century. The RTS,S/AS01 (Mosquirix) vaccine is the first and only in the world that has shown action against Plasmodium falciparum, a germ that contributes to the highest number of deaths from malaria. After passing the three phases...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Kazimierz Wielki University
2019-09-01
|
| Series: | Journal of Education, Health and Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/JEHS/article/view/26370 |
| _version_ | 1818009864713011200 |
|---|---|
| author | Iga Dudek Jakub Czarnota Danuta Hajduga Michał Dobrzyński Magdalena Marzęda |
| author_facet | Iga Dudek Jakub Czarnota Danuta Hajduga Michał Dobrzyński Magdalena Marzęda |
| author_sort | Iga Dudek |
| collection | DOAJ |
| description | Work on the malaria vaccine has been going on since the early 20st century. The RTS,S/AS01 (Mosquirix) vaccine is the first and only in the world that has shown action against Plasmodium falciparum, a germ that contributes to the highest number of deaths from malaria. After passing the three phases of clinical tests positively, the fourth phase was launched in 2019 - the MVIP program (The Malaria Vaccine Implementation Program). It covers three African countries: Kenya, Ghana and Modawi. Around 360,000 children are expected to receive the vaccine from these countries annually. The third phase of Mosquirix vaccine testing lasted five years (2009-2014) and was based on the extraction of 15 459 children and infants from seven African countries, followed by the administration of four doses of each medicine. In four years, among children aged 5-17 months who received 4 doses of Mosquirix, 4 out of 10 (39%) managed to prevent the development of malaria. The number of hospitalizations for malaria and severe anemia, which is one of the consequences of this disease, has also decreased significantly. In the fourth phase of the study, the role of the vaccine in reducing the number of deaths in children and its safety will be assessed in the context of routine, global use. Data from the MVIP program will include WHO recommendations on the wider use of the vaccine. |
| first_indexed | 2024-04-14T05:48:19Z |
| format | Article |
| id | doaj.art-2c5ae3202823436cb0dda2edb4eae5b1 |
| institution | Directory Open Access Journal |
| issn | 2391-8306 |
| language | English |
| last_indexed | 2024-04-14T05:48:19Z |
| publishDate | 2019-09-01 |
| publisher | Kazimierz Wielki University |
| record_format | Article |
| series | Journal of Education, Health and Sport |
| spelling | doaj.art-2c5ae3202823436cb0dda2edb4eae5b12022-12-22T02:09:13ZengKazimierz Wielki UniversityJournal of Education, Health and Sport2391-83062019-09-0198The world's first malaria vaccine – promising clinical resultsIga Dudek0Jakub Czarnota1Danuta Hajduga2Michał Dobrzyński3Magdalena Marzęda4Student Research Circle at the Department of Epidemiology and Clinical Research Methodology, Medical University of LublinStudent Research Circle at the Department of Epidemiology and Clinical Research Methodology, Medical University of LublinStudent Research Circle at the Department of Epidemiology and Clinical Research Methodology, Medical University of LublinStudent Research Circle at the Department of Epidemiology and Clinical Research Methodology, Medical University of LublinStudent Research Circle at the Department of Epidemiology and Clinical Research Methodology, Medical University of LublinWork on the malaria vaccine has been going on since the early 20st century. The RTS,S/AS01 (Mosquirix) vaccine is the first and only in the world that has shown action against Plasmodium falciparum, a germ that contributes to the highest number of deaths from malaria. After passing the three phases of clinical tests positively, the fourth phase was launched in 2019 - the MVIP program (The Malaria Vaccine Implementation Program). It covers three African countries: Kenya, Ghana and Modawi. Around 360,000 children are expected to receive the vaccine from these countries annually. The third phase of Mosquirix vaccine testing lasted five years (2009-2014) and was based on the extraction of 15 459 children and infants from seven African countries, followed by the administration of four doses of each medicine. In four years, among children aged 5-17 months who received 4 doses of Mosquirix, 4 out of 10 (39%) managed to prevent the development of malaria. The number of hospitalizations for malaria and severe anemia, which is one of the consequences of this disease, has also decreased significantly. In the fourth phase of the study, the role of the vaccine in reducing the number of deaths in children and its safety will be assessed in the context of routine, global use. Data from the MVIP program will include WHO recommendations on the wider use of the vaccine.https://apcz.umk.pl/JEHS/article/view/26370malariathe MVIP programmevaccine |
| spellingShingle | Iga Dudek Jakub Czarnota Danuta Hajduga Michał Dobrzyński Magdalena Marzęda The world's first malaria vaccine – promising clinical results Journal of Education, Health and Sport malaria the MVIP programme vaccine |
| title | The world's first malaria vaccine – promising clinical results |
| title_full | The world's first malaria vaccine – promising clinical results |
| title_fullStr | The world's first malaria vaccine – promising clinical results |
| title_full_unstemmed | The world's first malaria vaccine – promising clinical results |
| title_short | The world's first malaria vaccine – promising clinical results |
| title_sort | world s first malaria vaccine promising clinical results |
| topic | malaria the MVIP programme vaccine |
| url | https://apcz.umk.pl/JEHS/article/view/26370 |
| work_keys_str_mv | AT igadudek theworldsfirstmalariavaccinepromisingclinicalresults AT jakubczarnota theworldsfirstmalariavaccinepromisingclinicalresults AT danutahajduga theworldsfirstmalariavaccinepromisingclinicalresults AT michałdobrzynski theworldsfirstmalariavaccinepromisingclinicalresults AT magdalenamarzeda theworldsfirstmalariavaccinepromisingclinicalresults AT igadudek worldsfirstmalariavaccinepromisingclinicalresults AT jakubczarnota worldsfirstmalariavaccinepromisingclinicalresults AT danutahajduga worldsfirstmalariavaccinepromisingclinicalresults AT michałdobrzynski worldsfirstmalariavaccinepromisingclinicalresults AT magdalenamarzeda worldsfirstmalariavaccinepromisingclinicalresults |